S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Here's something only a handful of people know (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Here's something only a handful of people know (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Here's something only a handful of people know (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Here's something only a handful of people know (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Las Vegas ballpark pitch revives debate over public funding for sports stadiums
“Amazon Loophole” could hand you $28,544 in “royalty” payouts (Ad)
Twitter executive responsible for content safety resigns after Elon Musk criticism
Slow start to New York's legal pot market leaves farmers holding the bag
NYSE:TAK

Takeda Pharmaceutical (TAK) Stock Forecast, Price & News

$16.12
+0.23 (+1.45%)
(As of 06/2/2023 ET)
Compare
Today's Range
$16.04
$16.15
50-Day Range
$15.84
$17.11
52-Week Range
$12.28
$17.15
Volume
1.29 million shs
Average Volume
2.06 million shs
Market Capitalization
$51.01 billion
P/E Ratio
20.94
Dividend Yield
1.67%
Price Target
$24.67

Takeda Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
53.0% Upside
$24.67 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
0.40mentions of Takeda Pharmaceutical in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

347th out of 983 stocks

Pharmaceutical Preparations Industry

160th out of 486 stocks


TAK stock logo

About Takeda Pharmaceutical (NYSE:TAK) Stock

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Receive TAK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Takeda Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

TAK Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Takeda Pharmaceutical (NYSE: TAK)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
See More Headlines

TAK Price History

TAK Company Calendar

Today
6/04/2023
Next Earnings (Estimated)
7/27/2023
Fiscal Year End
3/31/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
47,347
Year Founded
1781

Price Target and Rating

Average Stock Price Forecast
$24.67
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+53.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

Net Income
$2.35 billion
Pretax Margin
9.31%

Debt

Sales & Book Value

Annual Sales
$29.81 billion
Cash Flow
$3.64 per share
Book Value
$14.86 per share

Miscellaneous

Outstanding Shares
3,164,620,000
Free Float
3,163,350,000
Market Cap
$51.01 billion
Optionable
Optionable
Beta
0.63

Social Links


Key Executives

  • Christophe Weber
    President, CEO & Representative Director
  • Constantine Saroukos
    Chief Financial Officer & Director
  • Andrew S. Plump
    Director, President-Research & Development
  • Michael E. Mendelsohn
    Chief Medical & Scientific Officer
  • Norimasa Takeda
    Chief Accounting Officer & Corporate Controller













TAK Stock - Frequently Asked Questions

Should I buy or sell Takeda Pharmaceutical stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TAK shares.
View TAK analyst ratings
or view top-rated stocks.

What is Takeda Pharmaceutical's stock price forecast for 2023?

5 analysts have issued twelve-month price targets for Takeda Pharmaceutical's shares. Their TAK share price forecasts range from $20.00 to $30.00. On average, they anticipate the company's share price to reach $24.67 in the next twelve months. This suggests a possible upside of 53.0% from the stock's current price.
View analysts price targets for TAK
or view top-rated stocks among Wall Street analysts.

How have TAK shares performed in 2023?

Takeda Pharmaceutical's stock was trading at $15.60 at the beginning of 2023. Since then, TAK shares have increased by 3.3% and is now trading at $16.12.
View the best growth stocks for 2023 here
.

When is Takeda Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our TAK earnings forecast
.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical (NYSE:TAK) pays an annual dividend of $0.27 per share and currently has a dividend yield of 1.70%. The dividend payout ratio is 35.07%. This payout ratio is at a healthy, sustainable level, below 75%.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2023 earnings guidance on Friday, May, 12th. The company provided earnings per share guidance of $3.28-$3.28 for the period. The company issued revenue guidance of $29.03 billion-$29.03 billion.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.15%), Mondrian Investment Partners LTD (0.13%), Macquarie Group Ltd. (0.12%), Macquarie Group Ltd. (0.12%), Renaissance Technologies LLC (0.09%) and BlackRock Inc. (0.08%).

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $16.12.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical (NYSE:TAK) has a market capitalization of $51.01 billion and generates $29.81 billion in revenue each year. The company earns $2.35 billion in net income (profit) each year or $0.77 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

The company employs 47,347 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?
The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.
Read More
How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The official website for the company is www.takeda.com. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.

This page (NYSE:TAK) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -